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Abstract 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder second only to 
Alzheimer’s disease. Diagnosis remains clinical, based on phenotypic patterns. In the 
last decade many attempts to develop early differential pre-clinical markers have 
been reported. In this presentation, the molecular risk factors that may link between 
the etiopathogenesis leading to PD and peripheral markers will be discussed. 
Genetic variation known to be involved in familial forms of PD will be shown to be 
linked to sporadic cases, as for example leucine-rich repeat kinase 2 (LRRK2) that 
was found to regulate microRNA-mediated translation regulation. In addition 
postmortem microarray findings of transcription alterations will be compared to the 
peripheral findings of mRNA profiles. Molecular processes involved in ubiquitination 
and proteasome, autophagy, mitochondrial dysfunction and the nicotinic and 
adenosine A2 protection will be discussed. The question of what time-point should be 
used measuring the different markers and the course of the disease considered, and 
the future possibilities in exploring these techniques will be debated. 
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Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder second only to 
Alzheimer’s disease. Since the fact that diagnosis remains clinical based on the 
presence of a combination of cardinal signs, including rest tremor, bradykinesia, 
rigidity, and loss of postural reflexes, the diagnosis will most often be made  after 
more than 70-80% of the dopaminergic neurons have degenerated [1]. There is wide 
agreement that a preclinical approach detecting at-risk PD subjects would enable 
earlier preventive therapy that might slow down or even stop the neurodegeneration. 
In this review the molecular risk factors will be described, beginning with familial 
genetic findings and continuing with transcription profile studies in the central nervous 
system (CNS)that have been studied postmortem to the new findings of transcription 
factors, alterations found in peripheral blood samples, which link some again to 
familial genetic forms. 
Since the discovery of the first disease-causing mutation in the -synuclein gene 
(SNCA/ PARK1/4), a number of genes and loci have been implicated in PD denoted 
as PARK1 to 14. Those genes harboring mutations that cause late-onset dominantly 
inherited PD include SNCA and leucine-rich repeat kinase 2 (LRRK2/PARK8), 
whereas early-onset recessive parkinsonism is associated with homozygous and 
compound heterozygous mutations in parkin (PRKN/PARK2), Pten-induced kinase 1 
(PINK1/PARK6) and Oncogene DJ-1 (DJ-1/PARK7) [2]. Despite their importance in 
identifying key molecules in the pathogenesis of PD, these genetic mutations remain 
relatively rare (less than 5%). On the other hand, association studies in sporadic PD 
have found that similar genes such as SNCA polymorphism, as well as microtubule-
associated protein tau/saitohin (MAPT/STH), glucoberebrosidase (GBA) and LRRK2 
are associated with the risk of PD, but as the highest odds ratio after meta-analysis 
reaches 3.4 it must still be validated in larger and diverse population [3].  
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As an additional approach to finding new candidate molecules involved in the 
etiopathogenesis of PD, many gene expression studies have been conducted on 
postmortem brain tissue, especially on the substantia nigra (SN), the affected brain 
region (for review see Table 1).  
Studying the various reports and different brain regions reveals the involvement of 
protein metabolism and handling (e.g. aggregation and ubiquitination processes, 
proteasome and vesicular trafficking), the energy pathway including the mitochondria, 
the response to stress (e.g. heat shock proteins and their chaperones), the 
autophagy processes, inflammation, adenosine receptors (caffeine) as well as 
oxidative metabolism (Table 1). In addition, in many of the postmortem studies found 
a link between familial to sporadic PD, with the finding of alterations in the 
transcription of SNCA [6, 8, 9, 12], which may point to a common neurodegeneration 
mechanism in both cases. Similarly, UCHL-1 (PARK5) and DJ-1 (PARK7) mRNA 
were found to alter in sporadic PD [4-6, 10].  
As the availability of postmortem brain tissue is limited, as well as the need for early 
diagnosis research has been directed  to the periphery, with the aim of finding similar 
alterations there as in the CNS. Indeed, such alterations have been confirmed [6]. As 
in the postmortem brain studies, many of the molecular pathways discovered in the 
first approach have also been found in the periphery (Table 1). TRIM24 mRNA was 
found to alter its expression in peripheral blood both in sporadic PD as well as in 
carriers of the PARK2 or LRRK2 mutations [19]. TRIM24 is involved in the 
transcription control of some nuclear receptors, but was also found to be involved in 
the control of apoptosis and autophagia mechanisms. Therefore it could be 
hypothesized that this marker may point to the common mechanism involving 
autophagy and oxidative stress leading to apoptosis. In PD carriers of the LRRK2 
mutation gene expression profiles in blood samples revealed the involvement of the 
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ubiquitin-proteasome system [18]. Again, also in this study one can conclude similar 
molecular pathways of the protein metabolism to be involved both in sporadic and 
familial PD. In a familial PD study with duplications of the SNCA gene it was shown 
that this duplication directly influences the expression of the SNCA mRNA in blood 
[18]. This finding enhances the notion of the involvement of SNCA in the 
etiopathology of PD. 
From the current findings, it could be concluded that peripheral molecular markers 
can mirror the disease processes and may be even detect progression of the 
disease. Of course, the path is still long, in order to reach the best set of markers that 
will best provide early differential diagnosis for PD. But such future perspectives 
seem to be nearing. For such an aim, there is a need for a longitudinal large scale 
international study, in which at-risk subjects will be followed up for their progression 
to PD phenotypes while in parallel different markers will be collected, as for example 
peripheral blood samples (for DNA/ genotypes, RNA/ transcriptomics and proteins/ 
proteomics), imaging data as well as later on for conformational diagnosis, 
postmortem brain tissue should be collected when possible. Of course, since the data 
produced from such large gene wide analysis is huge and quite complicated there is 
need for interdisciplinary work field including molecular biologists, imaging experts, 
clinicians and bioinformatics specialist who can work this mass of information into 
comprehensive data. Such an approach could unravel new and common mechanism 
both involved in familial and sporadic PD that may lead to some new models for the 
neuropathophysiology causing this neurodegeneration. Still the main question of the 
time point, when one should start the diagnosis for PD, is not yet answered. The 
main reason to this is the fact that therapy should be available in order to slow-down 
or stop the progress of the disease. But also ethical aspects are involved. 
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Table 1: Summary of transcription (RNA) profiles in postmortem brain tissue and 
peripheral blood samples from Parkinson’s disease subjects (modified from [4, 5]) 
Samples origin Region /cell 
type 
Method of 
measurements 
Genes found Familial / 
Sporadic PD / 
HC 
Reference / the 
research group 
CNS SN Affymetrix HG-
Focus array 
PSMA2-5 
HIP2 
SKP1A 
GBE1 
UQCRC2 
ALDH1A1 
LAMB2 
DNAJB5 (Hsp40) 
HSPA8 
Sporadic [6] 
Grünblatt and 
colleagues 2004 
SN, Putamen, 
BA9 
Affymetrix U133A 
GeneChip 
NEFL 
HSPB1 
FGF13 
NSF 
SNAP25 
SYT1 
Sporadic [5] 
Zhang and 
colleagues 2005 
SN Affymetrix U133A 
GeneChip 
HSPA1A-B 
SYT1 
UBE1 
Sporadic [5] 
Hauser and 
colleagues 2005 
LB-containing DA 
neurons vs. non-
LB-containing DA 
neurons 
RNA fingerprinting STCH (Hsp70) 
USP8 
ANP32B 
 [7] 
SN medial / 
lateral 
Affymetrix U133A & 
B GeneChip 
NEFL 
HIP2 
HSPB1 
UCHL-1 
GBE1 
ALDH1A1 
FGF13 
NSF 
SNAP25 
Sporadic [4, 5] 
Moran and 
colleagues 2006 
Duke and 
colleagues 2006 
SN, Striatum CodeLink Human UCHL-1 Sporadic [5] 
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Samples origin Region /cell 
type 
Method of 
measurements 
Genes found Familial / 
Sporadic PD / 
HC 
Reference / the 
research group 
UniSet 20 K 
bioarray 
FGF13 
NSF 
SYN1-2 
SYT1 
STX1A 
Miller and 
colleagues 2006 
Putamen, 
occipital cortex, 
cerebellar 
hemispheres 
Affymetrix U133A 
GeneChip 
NPY 
HTR2C 
SYT1 
Sporadic [5] 
Vogt and 
colleagues 2006 
SN, vetral 
tegmental area, 
perirhinal corte 
(BA35), insular 
cortex, 
amygdale, 
nucleus basalis, 
caudate, 
putamen, 
nucleus 
accumbens, 
golobus pallidus, 
mediodorsal 
thalamus, 
pulvinar, 
subthalamic 
nucleus, dorsal 
nucleus of the 
vagus nerve, 
cerebellar 
hemisphere, 
anterior 
cerebellar 
vermis, dorsal 
raphe, locus 
ceruleus, 
Affymetrix Human 
Genome U133 Plus 
2.0 GeneChip 
MRPS6 
STIP 
Sporadic [5] 
Papapetropoulos 
and colleagues 
2006 
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Samples origin Region /cell 
type 
Method of 
measurements 
Genes found Familial / 
Sporadic PD / 
HC 
Reference / the 
research group 
hypothalamus, 
hippocampus, 
reticular 
formation 
Midbrain-SN qRT-PCR SNCA Sporadic [6] 
Chiba-Falek and 
colleagues 2006 
SN, amygdala qRT-PCR SNCA Sporadic [6] 
Papapetropoulos 
and colleagues 
2007 
SN, cerebellum qRT-PCR, 
Genotyping 
SNCA Sporadic [8] 
NM-containing 
DA SN neurons 
qRT-PCR SNCA 
TH 
ENO2 
Sporadic [6] 
Gründemann and 
colleagues 2008 
NM-containing 
DA SN neurons 
Affymetrix U133A 
GeneChip 
SNCA 
UCHL-1 
HIP2 
PINK1 
SOD1 
HSPA8 
UBE1-3 
PSMB4-5/C3/D4 
SYN1 
NSF 
SYT1 
Sporadic [6] 
Simunovic and 
colleagues 2009 
SN, amygdala qRT-PCR SEPT4 
SNCA 
Sporadic [9] 
Putamen, frontal 
cortex, parietal 
cortex,  
amygdala, 
cerebellum 
qRT-PCR DJ-1 Sporadic [10] 
Putamen qRT-PCR A2AAR Sporadic [11] 
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Samples origin Region /cell 
type 
Method of 
measurements 
Genes found Familial / 
Sporadic PD / 
HC 
Reference / the 
research group 
SN, amygdala qRT-PCR SEPT4 
SNCA 
Sporadic [12] 
BA9 In-situ hybridization; 
One-Color Agilent 
60-mer Whole 
Human Genome 
Microarray 
GAD76 Sporadic [13] 
SN genome-wide meta-
analysis 
PGC-1alpha Sporadic [2] 
Peripheral blood lymphocytes Semi-quantitative 
PCR 
D3R Sporadic [14] 
PBMC Semi-quantitative 
PCR 
MxA Sporadic [15] 
Whole blood Affymetrix U133A 
GeneChip 
ST13 
HIP2 
CLTB 
Sporadic [2] 
Scherzer and 
colleagues 2007 
Whole blood Affymetrix U133A 
GeneChip; 
CodeLink; Stanford 
SNCA 
ALAS2 
FECH 
BLVRB 
HC [2] 
Scherzer and 
colleagues 2008 
Whole blood Affymetrix U133A 
GeneChip 
SNCA 
DBH 
ST13 
Sporadic [16] 
PBMC Semi-quantitative 
PCR 
MIP-1 alpha 
MCP-1 
IL-8 
IL-1 beta 
IFN gama 
TNF alpha 
Sporadic [17] 
Whole blood qRT-PCR PSMA2-5 
LAMB2 
ALDH1A 
HIP2 
HIST1H3E 
Sporadic [6] 
lymphocytes qRT-PCR A2AAR Sporadic [11] 
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Samples origin Region /cell 
type 
Method of 
measurements 
Genes found Familial / 
Sporadic PD / 
HC 
Reference / the 
research group 
Whole blood Affymetrix 
Exon_ST1 
SRRM2 long isoform Sporadic [12] 
PBMC Agilent one-colour 
whole human 
genome 44K 
microarray; 
Genotyping 
ALAS2, 
ARG1 
DUSP10 
ERAF 
IFNG 
LTF 
SELENBP1 
UTG2B17 
PD carriers of 
LRRK2 mutation 
[18] 
Mutez and 
colleagues 2010 
Whole blood Affymetrix Human 
Gene 1.0 st. 
TRIM24 Sporadic; 
PARK2, PARK8 
[19] 
leukocytes qRT-PCR; 
comparative 
genomic 
hybridization; one-
color whole human 
genome 44K 
microarrays 
SNCA 
FAM13A 
Familial with 
SNCA 
duplication 
[18] 
Annotation: A2AAR, adenosine 2A receptor; ALAS2, 5-aminolevulinate synthase 2; ALDH1A1, 
aldehyde dehydrogenase 1 family member A1; ANP32B, acidic (leucine-rich) nuclear phosphoprotein 
32; ARG1, arginase, liver; BA9, Brodmann’s Area 9; BLVRB, biliverdin reductase B; CLTB, clathrin, 
light chain B; CNS, central nervous system; D3R, dopamine receptor D3; DA, dopaminergic; DBH, 
dopamine beta-hydroxylase; DJ-1, PARK7; DNAJB5, DnaJ (Hsp40) homologue, subfamily B, member 
5; DUSP10, dual specificity phosphatase 10; ENO2, neuron-specific enolase; ERAF, Erythroid 
associated factor; FAM13A, family with sequence similarity 13, member A; FECH, ferochelatase; 
FGF13, fibroblast growth factor 13; GBE1, Glucan (1,4--), branching enzyme 1 (glucagen branching 
enzyme, Andersen disease, glycogen storage disease type IV); HC, healthy controls; GAD67, glutamic 
acid decarboxylase 67kDa isoform; HIP2, huntigntin interacting protein 2 (PARK5); HIST1H3E, histone 
cluster-1 H3e; HSPA1A-B, heat shock protein A1A-B; HSPA8, Heat shock protein A8; HSPB1, heat 
shock 27 kDa protein 1; HTR2C, 5-hyproxytryptamine (serotonin) receptor 2C; IFNG, Interferon 
gamma; IR, insulin receptor, LAMB2, laminin, beta-2 (laminin S); LB, Lewy Bodies; LTF, 
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Lactotransferrin; MRPS6, mitochondrial ribosomal protein S6; NEFL, neurofilament, light polypeptide; 
NM, neuromelanin; NPY, neuropeptide Y; NSF, N-ethyl maleimide-sensitive factor; PBMC, peripheral 
blood momonuclear cells; PD, Parkinson’s disease; PGC-1a, proliferator–activated receptor gama 
coactivator-1alpha PINK1, PTEN induced putative kinase 1 (PARK6); PSMA2-5, proteasome subunit 
alpha type 2-5; PSMB4-5/C3/D4, proteasome (prosome, macropain) subunit beta type 4-5/ 26S 
subunit ATPase3/ non-ATPase 4; qRT-PCR, quantitative RT-PCR; SELENBP1, Selenium binding 
protein 1; SEPT4, septin 4; SKP1A, S-phase kinase-associated protein 1A (p19A); SN, substantia 
nigra; SNAP25, synaptosomal-assocoated protein; SNCA, Alpha-synuclein (PARK1); SOD1, 
superoxide disomutase 1; SRRM2, serine/arginine repetitive matrix 2; ST13, suppression of 
tumorigenicity 13; STCH, stress 70 protein chaperone; STIP1, stress-induced phosphoprotein 1 (Hsp 
70/Hsp90-organizing protein); STX1A, syntaxin 1A; SYN1-2. synapsin 1-2; SYT1, synaptotagmin 1, 
TH, tyrosine hydroxylase; TRIM24, tripartite motif containing 24; UBE1, ubiquitin-activating enzyme E1 
UCHL-1, ubiquitin C-terminal hydrolase (PARK5); UQCRC2, Ubiquinol-cytochrome c reductase core 
protein II; USP8, ubiquitin specific protease 8; UTG2B17, UDP glucuronosyl transferase 2, B17; 
 
